UroGen Pharma Ltd. — Director's Dealing 2020

Jan 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-01-03

Reporting Person: Barrett Elizabeth A. (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-03	Ordinary Shares	M	105688	$0.00	Acquired	122236	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-03	Ordinary Shares	$	M	105688	Disposed		Ordinary Shares (105688)	Direct

Footnotes

F1: Represents the settlement of restricted stock units that vested on January 3, 2020 through the issuance of ordinary shares.

F2: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F3: On January 3, 2018, the reporting person was granted 317,065 restricted stock units of which 33% vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter.